To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Therapeutic efficacy of a… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Therapeutic efficacy of alpha-radioimmunotherapy with different activity levels of the Bi-213-labeled monoclonal antibody MX35 in an ovarian cancer model

Journal article
Authors Anna Gustafsson-Lutz
Tom Bäck
Emma Aneheim
Ragnar Hultborn
Stig Palm
Lars Jacobsson
A. Morgenstern
F. Bruchertseifer
Per Albertsson
Sture Lindegren
Published in EJNMMI Research
Volume 7
ISSN 2191-219X
Publication year 2017
Published at Institute of Clinical Sciences, Department of Radiation Physics
Institute of Clinical Sciences, Department of Oncology
Language en
Keywords Radioimmunotherapy, Dosimetry, High LET radiation, Monoclonal antibodies (mAb), CARCINOMA ASCITES-CELLS, NUDE-MICE, AT-211-MX35 F(AB')(2), LONG-TERM, PHARMACOKINETICS, MYELOTOXICITY, IRRADIATION, DOSIMETRY, BINDING, TH-229
Subject categories Cancer and Oncology


Background: The aim of this study was to compare the therapeutic efficacy of two different activity levels of the Bi-213-labeled monoclonal antibody MX35 in an ovarian cancer model. Sixty female BALB/c (nu/nu) mice were inoculated intraperitoneally with human ovarian cancer cells (OVCAR-3). Two weeks later, 40 mice were injected intraperitoneal (i.p.) with 1 ml of Bi-213-MX35, 3 MBq/mL (n = 20), or 9 MBq/mL (n = 20). An additional 20 mice received unlabeled MX35. Incidence of tumors and ascites was investigated 8 weeks after therapy. Body weight and white blood cell counts were monitored after treatment for possible signs of toxicity. Results: The tumor-free fraction of the animals treated with 3 MBq/mL of Bi-213-MX35 was 0.55, whereas that of animals treated with 9 MBq/mL of Bi-213-MX35 was 0.78. The control group treated with unlabeled MX35 had a tumor-free fraction of 0.15. No significant reduction in white blood cell counts or weight loss was observed. Conclusions: Tumor growth after i.p. treatment with Bi-213-MX35 was significantly reduced compared to treatment with unlabeled MX35. Treatment with 9 MBq/mL of Bi-213-MX35 resulted in higher tumor-free fraction compared with 3 MBq/mL of Bi-213-MX35, but this difference was not statistically significant. No signs of toxicity were observed in the treated animals.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?